182 related articles for article (PubMed ID: 35167895)
1. The effects of estrogen on targeted cancer therapy drugs.
Zhao Y; Wang X; Liu Y; Wang HY; Xiang J
Pharmacol Res; 2022 Mar; 177():106131. PubMed ID: 35167895
[TBL] [Abstract][Full Text] [Related]
2. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
Wu W; Xue X; Chen Y; Zheng N; Wang J
Pharmacol Res; 2022 Oct; 184():106456. PubMed ID: 36116709
[TBL] [Abstract][Full Text] [Related]
3. The role of ERα36 in cell type-specific functions of estrogen and cancer development.
Mahboobifard F; Dargahi L; Jorjani M; Ramezani Tehrani F; Pourgholami MH
Pharmacol Res; 2021 Jan; 163():105307. PubMed ID: 33246174
[TBL] [Abstract][Full Text] [Related]
4. Estrogen can restore Tamoxifen sensitivity in breast cancer cells amidst the complex network of resistance.
Mansouri S; Farahmand L; Hosseinzade A; Eslami-S Z; Majidzadeh-A K
Biomed Pharmacother; 2017 Sep; 93():1320-1325. PubMed ID: 28747013
[TBL] [Abstract][Full Text] [Related]
5. Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death.
Leignadier J; Dalenc F; Poirot M; Silvente-Poirot S
Biochem Pharmacol; 2017 Nov; 144():18-28. PubMed ID: 28642035
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan: 25 years of cancer treatment.
Bailly C
Pharmacol Res; 2019 Oct; 148():104398. PubMed ID: 31415916
[TBL] [Abstract][Full Text] [Related]
7. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
8. Autophagy as a molecular target for cancer treatment.
Kocaturk NM; Akkoc Y; Kig C; Bayraktar O; Gozuacik D; Kutlu O
Eur J Pharm Sci; 2019 Jun; 134():116-137. PubMed ID: 30981885
[TBL] [Abstract][Full Text] [Related]
9. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Ko JC; Chiu HC; Syu JJ; Jian YJ; Chen CY; Jian YT; Huang YJ; Wo TY; Lin YW
Biochem Pharmacol; 2014 Mar; 88(1):119-27. PubMed ID: 24447935
[TBL] [Abstract][Full Text] [Related]
11. Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin.
Barbolina MV
Pharmacol Res; 2021 Jun; 168():105585. PubMed ID: 33798735
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.
Lernoux M; Schnekenburger M; Dicato M; Diederich M
Pharmacol Res; 2018 Mar; 129():337-356. PubMed ID: 29133216
[TBL] [Abstract][Full Text] [Related]
13. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
14. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy.
Wang S; Fu JL; Hao HF; Jiao YN; Li PP; Han SY
Pharmacol Res; 2021 Aug; 170():105728. PubMed ID: 34119622
[TBL] [Abstract][Full Text] [Related]
15. The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.
Ayoub NM; Siddique AB; Ebrahim HY; Mohyeldin MM; El Sayed KA
Eur J Pharmacol; 2017 Sep; 810():100-111. PubMed ID: 28625568
[TBL] [Abstract][Full Text] [Related]
16. Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies.
Wang Y; Xie Q; Tan H; Liao M; Zhu S; Zheng LL; Huang H; Liu B
Pharmacol Res; 2021 Nov; 173():105702. PubMed ID: 34102228
[TBL] [Abstract][Full Text] [Related]
17. Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand?
Martins-Neves SR; Cleton-Jansen AM; Gomes CMF
Pharmacol Res; 2018 Nov; 137():193-204. PubMed ID: 30316903
[TBL] [Abstract][Full Text] [Related]
18. Targeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy.
Rajagopal C; Lankadasari MB; Aranjani JM; Harikumar KB
Pharmacol Res; 2018 Apr; 130():273-291. PubMed ID: 29305909
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Sampson A; Peterson BG; Tan KW; Iram SH
Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
[TBL] [Abstract][Full Text] [Related]
20. Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation.
Zhou JB; Tang D; He L; Lin S; Lei JH; Sun H; Xu X; Deng CX
Pharmacol Res; 2023 Aug; 194():106830. PubMed ID: 37343647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
